Platelet phospholipase A and thromboxane synthase pathway enzymes

The platelet phospholipase A and thromboxane synthase pathway enzymes constitute a multi-step enzymatic cascade essential for platelet activation and thrombus formation. The process begins with the liberation of arachidonic acid from membrane phospholipids by phospholipase A2 (PLA2), followed by its conversion into prostaglandin H2 by cyclooxygenase-1 (COX-1), and finally into thromboxane A2 (TXA2) by thromboxane synthase (TXAS) (UniProt P47712, UniProt P24557). TXA2 is a potent pro-aggregatory and vasoconstrictive mediator that plays a central role in physiological hemostasis and pathological thrombosis. Dysregulation or over-activation of this pathway is a major contributor to cardiovascular diseases, including myocardial infarction and ischemic stroke (StatPearls: Platelet Aggregation Inhibitors). Pharmacological agents such as aspirin and thromboxane synthase inhibitors (e.g., ozagrel) target these enzymes to reduce TXA2 levels and prevent arterial occlusion (PubChem CID 2244). However, therapeutic inhibition of this pathway is associated with an increased risk of bleeding and potential gastrointestinal side effects due to the impairment of normal platelet function and protective prostaglandin synthesis.

Other names

Arachidonic acid cascadeThromboxane A2 biosynthetic pathwayPlatelet TXA2 pathwayProstanoid biosynthetic pathway

Inhibition of the enzymatic conversion of arachidonic acid to thromboxane A2, thereby reducing platelet activation and aggregation.